SUMO-1 modification activates the transcriptional response of p53

EMBO Journal

Volumn 18, Issue 22, 1999, Pages 6455-6461

  Rodriguez, Manuel S ^a   Desterro, Joana M P ^a   Lain, Sonia ^b   Midgley, Carol A ^b   Lane, David P ^b   Hay, Ronald T ^a  

^a UNIVERSITY OF ST ANDREWS   (United Kingdom)

^b UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

mdm2; p53; SUMO 1; Ubiquitin

Indexed keywords

LYSINE; PROTEIN P53; UBIQUITIN;

ARTICLE; CARBOXY TERMINAL SEQUENCE; CONTROLLED STUDY; GENE MUTATION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN MODIFICATION; TRANSCRIPTION INITIATION; TRANSCRIPTION REGULATION;

BINDING SITES; GENES, P53; HUMANS; LIGASES; RECOMBINANT PROTEINS; SEQUENCE DELETION; SUMO-1 PROTEIN; TRANS-ACTIVATION (GENETICS); TRANSFECTION; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53; UBIQUITIN-CONJUGATING ENZYMES; UBIQUITINS;

EID: 0033571214     PISSN: 02614189     EISSN: None     Source Type: Journal    
DOI: 10.1093/emboj/18.22.6455     Document Type: Article

References (63)

1. Arenzana-Seisdedos, F., Thompson, J., Rodriguez, M.S., Bachelerie, F., Thomas, D. and Hay, R.T. (1995) Inducible nuclear expression of newly synthesized IκBα negatively regulates DNA-binding and transcriptional activities of NF-κB. Mol. Cell. Biol., 15, 2689-2696.
2. Arenzana-Seisdedos, F., Turpin, P., Rodriguez, M., Thomas, D., Hay, R.T., Virelizier, J.L. and Dargemont, C. (1997) Nuclear localization of IκBα promotes active transport of NF-κB from the nucleus to the cytoplasm. J. Cell Sci., 110, 369-378.
3. Armstrong, J.F., Kaufman, M.H., Harrison, D.J. and Clarke, A.R. (1995) High-frequency developmental abnormalities in p53-deficient mice. Curr. Biol., 5, 931-936.
4. Barak, Y., Juven, T., Haffner, R. and Oren, M. (1993) mdm2 expression is induced by wild type p53 activity. EMBO J., 12, 461-468.
5. Boddy, M.N., Howe, K., Etkin, L.D., Solomon, E. and Freemont, P.S. (1996) Pic-1, a novel ubiquitin-like protein which interacts with the PML component of a multiprotein complex that is disrupted in acute promyelocytic leukemia. Oncogene, 13, 971-982.
6. Bottger, A., Bottger, V., Sparks, A., Liu, W.L., Howard, S.F. and Lane, D.P. (1997) Design of a synthetic Mdm2-binding mini protein that activates the p53 response in vivo. Curr. Biol., 7, 860-869.
7. Brugarolas, J., Chandrasekaran, C., Gordon, J.I., Beach, D., Jacks, T. and Hannon, G.J. (1995) Radiation-induced cell cycle arrest compromised by p21 deficiency. Nature, 377, 552-557.
8. Chen, J., Marechal, V. and Levine, A.J. (1993) Mapping of the p53 and mdm-2 interaction domains. Mol. Cell. Biol., 13, 4107-4114.
9. Desterro, J.M.P., Thomson, J. and Hay, R.T. (1997) Ubch9 conjugates SUMO but not ubiquitin. FEBS Lett., 417, 297-300.
10. Desterro, J.M.P., Rodriguez, M.S. and Hay, R.T. (1998) SUMO-1 modification of IκBα inhibits NF-κB activation. Mol. Cell, 2, 233-239.
11. Desterro, J.M.P., Rodriguez, M.S., Kemp, G.D. and Hay, R.T. (1999) Identification of the enzyme required for activation of the small ubiquitin-like protein SUMO-1. J. Biol. Chem., 274, 10618-10624.
12. Donehower, L.A. (1996) The p53-deficient mouse: a model for basic and applied cancer studies. Semin. Cancer Biol., 7, 269-278.
13. Duprez, E. et al. (1999) SUMO-1 modification of the acute promyelocytic leukaemia protein PML: implications for nuclear localisation. J. Cell Sci., 112, 381-393.
14. Freedman, D.A. and Levine, A.J. (1998) Nuclear export is required for degradation of endogenous p53 by MDM2 and human papillomavirus E6. Mol. Cell. Biol., 18, 7288-7293.
15. Fritsche, M., Haessler, C. and Brandner, G. (1993) Induction of nuclear accumulation of the tumor-suppressor protein p53 by DNA-damaging agents. Oncogene, 8, 307-318.
16. Gong, L., Li, B., Millas, S. and Yeh, E.T. (1999) Molecular cloning and characterization of human AOS1 and UBA2, components of the sentrin-activating enzyme complex. FEBS Lett., 448, 185-189.
17. Hansen, S., Lane, D.P. and Midgley, C.A. (1998) The N terminus of the murine p53 tumour suppressor is an independent regulatory domain affecting activation and thermostability. J. Mol. Biol., 275, 575-588.
18. Harris, C.C. and Hollstein, M. (1993) Clinical implications of the p53 tumor-suppressor gene. N. Engl. J. Med., 329, 1318-1327.
19. Haupt, Y., Maya, R., Kazaz, A. and Oren, M. (1997) Mdm2 promotes the rapid degradation of p53. Nature, 387, 296-303.
20. Hershko, A. and Ciechanover, A. (1992) The ubiquitin system for protein degradation. Annu. Rev. Biochem., 61, 761-807.
21. ARF with Mdm2 inhibits ubiquitin ligase activity of Mdm2 for tumor suppressor p53. EMBO J., 18, 22-27.
22. Honda, R., Tanaka, H. and Yasuda, H. (1997) Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53. FEBS Lett., 420, 25-27.
23. Hsieh, J.K., Chan, F.S., O'Connor, D.J., Mittnacht, S., Zhong, S. and Lu, X. (1999) RB regulates the stability and the apoptotic function of p53 via MDM2. Mol. Cell, 3, 181-193.
24. Johnson, E.S. and Blobel, G. (1997) Ubc9p is the conjugating enzyme for the ubiquitin-like protein Smt3p. J. Biol. Chem., 272, 26799-26802.
25. Kamitani, T., Nguyen, H.P. and Yeh, E.T.H. (1997) Preferential modification of nuclear proteins by a novel ubiquitin-like molecule. J. Biol. Chem., 272, 14001-14004.
26. Kastan, M.B., Onyekwere, O., Sidransky, D., Vogelstein, B. and Craig, R.W. (1991) Participation of p53 protein in the cellular response to DNA damage. Cancer Res., 51, 6304-6311.
27. Ko, L.J. and Prives, C. (1996) p53: puzzle and paradigm. Genes Dev., 10, 1054-1072.
28. Kroll, M. et al. (1997) The carboxy-terminus of IκBα determines susceptibility to degradation by the catalytic core of the proteasome. Oncogene, 15, 1841-1850.
29. Kubbutat, M.H.G., Jones, S.N. and Vousden, K.H. (1997) Regulation of p53 stability by Mdm2. Nature, 387, 299-303.
30. Kubbutat, M.H., Ludwig, R.L., Ashcroft, M. and Vousden, K.H. (1998) Regulation of Mdm2-directed degradation by the C terminus of p53. Mol. Cell. Biol., 18, 5690-5698.
31. Kussie, P.H., Gorina, S., Marechal, V., Elenbaas, B., Moreau, J., Levine, A.J. and Pavletich, N.P. (1996) Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain. Science, 274, 948-953.
32. Lain, S., Midgley, C.A., Sparks, A., Lane, E.B. and Lane, D.P. (1999) An inhibitor of nuclear export activates the p53 response and induces the localisation of HDM2 and p53 to U1A-positive nuclear bodies associated with the PODs. Exp. Cell Res., 248, 457-472.
33. Lane, D.P. (1992) Cancer. p53, guardian of the genome. Nature, 358, 15-16.
34. Lane, D.P. (1998) Awakening angels. Nature, 394, 616-617.
35. Lu, X. and Lane, D.P. (1993) Differential induction of transcriptionally active p53 following UV or ionizing radiation: defects in chromosome instability syndromes? Cell, 75, 765-778.
36. Mahajan, R., Delphin, C., Guan, T., Gerace, L. and Melchior, F. (1997) A small ubiquitin-related polypeptide involved in targeting RanGAP1 to nuclear pore complex protein RanBP2. Cell, 88, 97-107.
37. Maki, C.G., Huibregtse, J.M. and Howley, P.M. (1996) In-vivo ubiquitination and proteasome-mediated degradation of p53. Cancer Res., 56, 2649-2654.
38. Maltzman, W. and Czyzyk, L. (1984) UV irradiation stimulates levels of p53 cellular tumor antigen in nontransformed mouse cells. Mol. Cell. Biol., 4, 1689-1694.
39. Marston, N.J., Jenkins, J.R. and Vousden, K.H. (1995) Oligomerisation of full length p53 contributes to the interaction with mdm2 but not HPV E6. Oncogene, 10, 1709-1715.
40. Matunis, M.J., Coutavas, E. and Blobel, G. (1996) A novel ubiquitin-like modification modulates the partitioning of the Ran-GTPase-activating protein RanGAP1 between the cytosol and the nuclear pore complex. J. Cell Biol., 135, 1457-470.
41. McCurrach, M.E., Connor, T.M., Knudson, C.M., Korsmeyer, S.J. and Lowe, S.W. (1997) Bax-deficiency promotes drug resistance and oncogenic transformation by attenuating p53-dependent apoptosis. Proc. Natl Acad. Sci. USA, 94, 2345-2349.
42. Midgley, C.A. and Lane, D.P. (1997) p53 protein stability in tumour cells is not determined by mutation but is dependent on Mdm2 binding. Oncogene, 15, 1179-1189.
43. Midgley, C.A., Fisher, C.J., Bartek, J., Vojtesek, B., Lane, D. and Barnes, D.M. (1992) Analysis of p53 expression in human tumours: an antibody raised against human p53 expressed in Escherichia coli. J. Cell Sci., 101, 183-189.
44. Momand, J., Zambetti, G.P., Olson, D.C., George, D. and Levine, A.J. (1992) The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell, 69, 1237-1245.
45. Muller, S., Matunis, M.J. and Dejean, A. (1998) Conjugation with the ubiquitin-related modifier SUMO-1 regulates the partitioning of PML within the nucleus. EMBO J., 17, 61-70.
46. Okuma, T., Honda, R., Ichikawa, G., Tsumagari, N. and Yasuda, H. (1999) In vitro SUMO-1 modification requires two enzymatic steps, E1 and E2. Biochem. Biophys. Res. Commun., 254, 693-698.
47. Oliner, J.D., Pietenpol, J.A., Thiagalingam, S., Gyuris, J., Kinzler, K.W. and Vogelstein, B. (1993) Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53. Nature, 362, 857-860.
48. Picksley, S.M., Vojtesek, B., Sparks, A. and Lane, D.P. (1994) Immunochemical analysis of the interaction of p53 with MDM2; fine mapping of the MDM2 binding site on p53 using synthetic peptides. Oncogene, 9, 2523-2529.
49. Pomerantz, J. et al. (1998) The Ink4a tumor suppressor gene product, p19Arf, interacts with MDM2 and neutralizes MDM2's inhibition of p53. Cell, 92, 713-723.
50. Rodriguez, M.S., Wright, J., Thomson, J., Thomas, D., Baleux, F., Virelizier, J.-L., Hay, R.T. and Arenzana-Seisdedos, F. (1996) Identification of lysine residues required for signal-induced ubiquitination and degradation of IκB-α in vivo. Oncogene, 12, 2425-2435
51. Rodriguez, M.S., Thompson, J., Hay, R.T. and Dargemont, C. (1999) Nuclear retention of IκBα protects it from signal-induced degradation and inhibits NF-κB transcriptional activation. J. Biol. Chem., 274, 9108-9115.
52. Rolfe, M., Beerromero, P., Glass, S., Eckstein, J., Berdo, J., Theodoras, A., Pagano, M. and Draetta, G. (1995) Reconstitution of p53-ubiquitinylation reactions from purified components: the role of human ubiquitin-conjugating enzyme Ubc4 and E6-associated protein (E6AP). Proc. Natl Acad. Sci. USA, 92, 3264-3268.
53. Roth, J., Dobbelstein, M., Freedman, D.A., Shenk, T. and Levine, A.J. (1998) Nucleo-cytoplasmic shuttling of the hdm2 oncoprotein regulates the levels of the p53 protein via a pathway used by the human immunodeficiency virus rev protein. EMBO J., 17, 554-564.
54. Saitoh, H., Pu, R., Cavenagh, M. and Dasso, M. (1997) RanBP2 associates with Ubc9p and a modified form of RanGAP1. Proc. Natl Acad. Sci. USA, 94, 3736-3741.
55. Saitoh, H., Sparrow, D.B., Shiomi, T., Pu, R.T., Nishimoto, T., Mohun, T.J. and Dasso, M. (1998) Ubc9p and the conjugation of SUMO-1 to RanGAP1 and RanBP2. Curr. Biol., 8, 121-124.
56. Schwarz, S.E., Matuschewski, K., Liakopoulos, D., Scheffner, M. and Jentsch, S. (1998) The ubiquitin-like proteins SMT3 and SUMO-1 are conjugated by the UBC9 E2 enzyme. Proc. Natl Acad. Sci. USA, 95, 560-564.
57. Shen, Z., Pardington-Purtymun, P.E., Comeaux, J.C., Moyzis, R.K. and Chen, D.J. (1996) UBL1, a human ubiquitin-like protein associating with human RAD51/RAD52 proteins. Genomics, 36, 271-279.
58. Shieh, S.Y., Ikeda, M., Taya, Y. and Prives, C. (1997) DNA damage-induced phosphorylation of p53 alleviates inhibition by MDM2. Cell, 91, 325-334.
59. Sternsdorf, T., Jensen, K. and Will, H. (1997) Evidence for covalent modification of the nuclear dot-associated proteins PML and Sp100 by PIC1/SUMO-1. J. Cell Biol., 139, 1621-1634.
60. Vojtesek, B-, Dolezalova, H., Lauerova, L., Svitakova, M., Havlis, P., Kovarik, J., Midgley, C.A. and Lane, D.P. (1995) Conformational changes in p53 analysed using new antibodies to the core DNA binding domain of the protein. Oncogene, 10, 389-393.
61. 1 arrest in human cancer cells. Cancer Res., 55, 5187-5190.
62. Wu, X., Bayle, J.H., Olson, D. and Levine, A.J. (1993) The p53-mdm-2 autoregulatory feedback loop. Genes Dev., 7, 1126-1132.
63. Yin, C., Knudson, C.M., Korsmeyer, S.J. and Van Dyke, T. (1997) Bax suppresses tumorigenesis and stimulates apoptosis in vivo. Nature, 385, 637-640.